Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”: [Ann Oncol 35 (2024) 1039-1047, (S0923753424037591), (10.1016/j.annonc.2024.08.2239)]

The authors regret that in the published Supplementary Material the sentence “Patients receiving the 0.7/0.4/20 mg mg regimen also received 10 mg oral dexamethasone 12–24 hours before the first split infusion, and 25 mg intravenous diphenhydramine and 650 mg oral acetaminophen 30–60 minutes before each odronextamab dose.“ should read as follows: Patients receiving the 0.7/4/20 mg regimen also received 10 mg oral dexamethasone 12–24 hours before the first split infusion, and 25 mg intravenous diphenhydramine and 650 mg oral acetaminophen 30–60 minutes before each odronextamab dose This has now been corrected in the Supplementary Material. The authors would like to apologise for any inconvenience caused.